A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
← catalyst calendarNCT05611801 · readout in 753 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
64
Countries
Argentina, Australia, Austria +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-09 | actual | When the study began enrolling |
| Primary completion | 2028-09-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-10 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hemophilia A
- Hemophilia B
Intervention
- Drug: marstacimab — also filed as PF-06741086
Primary outcomes
what the primary-completion date above is the date OFAnnualized bleeding rate (ABR) of treated bleeding events
measured Baseline to end of 12-month treatment period
Incidence of adverse events and serious adverse events
measured Screening through end of follow-up period (approximately 14 months)
Incidence and severity of thrombotic events
measured Baseline to end of 12-month treatment period
Incidence and severity of thrombotic microangiopathy
measured Baseline to end of 12-month treatment period
Incidence and severity of disseminated intravascular coagulation/consumption coagulopathy events
measured Baseline to end of 12-month treatment period
Immunogenicity (incidence of ADA and clinically significant persistent NAb against marstacimab)
measured Baseline to end of 12-month treatment period
Incidence and severity of injection site reaction
measured Baseline to end of 12-month treatment period
Incidence of severe hypersensitivity and anaphylactic reactions
measured Baseline to end of 12-month treatment period
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed